SHARONBIO

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 27-Feb-2023, regarding fire accident at the Company's manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja , Panvel, Dist: Raigad, Maharashtra. On basis of above the Company was required to clarify following:�� 1. Insurance amount claimed and realized by the listed entity for the loss/damage; 2. The actual amount of damage caused due to the natural calamity or other force majeure events; 3. Details of steps taken to restore normalcy and the

Members of the Exchange are hereby informed that the trading in equity shares of Sharon Bio-Medicine Limited (ISIN: INE028B01029) shall continue to be suspended pursuant to order dated May 17, 2023 passed by National Company Law Tribunal.

SHARONBIO: The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 18-Feb-2023, regarding strikes/lockouts/disturbances. On basis of above the Company was required to clarify following: 1. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.The response of the Company is attached.

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 27-Feb-2023, regarding fire accident at the Company's manufacturing unit located at M/s Sharon Bio-Medicine Limited, Plot No L6, MIDC Area, Taloja , Panvel, Dist: Raigad, Maharashtra. On basis of above the Company is required to clarify following:��1. Insurance amount claimed and realized by the listed entity for the loss/damage;2. The actual amount of damage caused due to the natural calamity or other force majeure events;3. Details of steps taken to restore normalcy and the imp

SHARONBIO: The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 18-Feb-2023, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.The response of the Company is awaited.

SHARONBIO: Members of the Exchange are hereby informed that the trading in Equity Shares of Sharon Bio-Medicine Limited shall be suspended w.e.f. March 29, 2019 (i.e. closing hours of trading on March 28, 2019) on account of Reduction of Share Capital

:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 28-Jan-2019, regarding 'Closure of operations of API plant '.". On basis of above the Company is required to clarify following: 1. Date of closure or estimated time of closure;2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year;The response of the Company is attached.

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 28-Jan-2019, regarding 'Closure of operations of API plant '.". On basis of above the Company is required to clarify following: 1. Date of closure or estimated time of closure;2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year;The response of the Company is awaited.

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that�� Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f�� January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is enclosed.Ms. Komal Mota is a qualified Company Secretary and LLB having more than 4 years of experience and worked with Listed and Private Companies.

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that�� Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f�� January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 06-Mar-2018, regarding " Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra 410208'.".On basis of above the Company is required to clarify following:1. Factory/unit where the strike/lock out takes place including reasons for such strike.<br>2. Estimated impact on the production/operations in case of strikes/lock outs;<br>3. Whether loss/damage covered by insuran

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 06-Mar-2018, regarding " Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra �� 410208'.". On basis of above the Company is required to clarify following: 1. Factory/unit where the strike/lock out takes place including reasons for such strike.<br> 2. Estimated impact on the production/operations in case of strikes/lock outs;<br> 3. Whether loss/damage covered b

Significant increase in price has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has submitted their response.

Significant increase in price has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

SHARONBIO: The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 14-Nov-2016, regarding "Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.". On basis of above the Company is required to clarify following: 1. Reasons

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 14-Nov-2016, regarding "Sharon Bio-Medicine Limited has informed the Exchange that As per audited annual accounts the accumulated losses had exceeded the net worth of the company as on March 31, 2016 and therefore company has decided to make Reference to Board for Industrial and Financial Reconstruction (BIFR) in accordance with the provisions of Sick Industrial Companies (Special Provisions) Act, 1985.".On basis of above the Company is required to clarify following:1. Reasons fo

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to recent news item captioned "USFDA approves Sharon Bio s Taloja API plant." The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has submitted their response.

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to recent news item captioned " USFDA approves Sharon Bio's Taloja API plant." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 12-Jan-2016 regarding the Board of Directors at their meeting held on January 12, 2016 have discussed the below:1. Closure of the subsidiary company M/s Yusur International FZE.On basis of above, the reply from the Company vide letter dated June 20, 2016 is attached.

SHARONBIO: The Exchange has sought clarification from the Company with respect to announcement dated January 12, 2016, that the Board of Directors at their meeting held on January 12, 2016 have discussed the Closure of the subsidiary company M/s Yusur International FZE. On basis of above Company is required to clarify following -1. The amount and percentage of the turnover or revenue or income and net worth contributed by such entity during the last financial year; 2. Impact on the Company due to Closure.The response of the Company is awaited.

Significant price movement has been observed in Sharon Bio-Medicine Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sharon Bio-Medicine Limited has informed the Exchange that "From 29th June 2015 at one of the manufacturing plant at MIDC, Taloja near Navi Mumbai the US FDA Audit is concluded and we are understanding the outcome of US FDA Inspection. The US FDA Audit was completed on 7th July 2015 night."

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated March 17 2015 that The Board of Directors at their meeting held on March 17, 2015 has decided to go with the restructuring of the debts of the company. On basis of above the Company is required to clarify following: a) Details and reasons for restructuring; b) Quantitative and/ or qualitative effect of restructuring; c) Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring; d) Brief details of change in shareholding pattern (if